All posts by imreal

DeCurtis Corporation Hires Camille Olivere As Senior Vice President Sales and Marketing


News Image

“The addition of Camille to our executive team brings extensive years of experience, both inside and outside of the hospitality space. We are looking forward to her driving our sales and marketing to new heights,”said Derek Fournier, President, and Chief Executive Officer, DeCurtis Corporation.

DeCurtis Corporation, the premier provider of location and proximity enabled solutions in complex indoor environments with a focus on health, safety and security, operational enhancement, and experience evolution is pleased to announce the hire of Camille Olivere as Senior Vice President of Sales and Marketing. Olivere is formerly the Senior Vice President of Sales at Norwegian Cruise Line, where she was instrumental in building a world-class sales organization and strengthening relationships and revenue with partners.    

“I am excited to join an executive team that is working toward increasing the health, safety, security, and overall guest experience through innovative technology, ” said Camille Olivere. “I look forward to leading the initiative to advance these company objectives to the travel industry and beyond.”

Olivere is an accomplished executive with over twenty years of experience in cruise, travel, and technology industries holding key roles in development and sales. Previously she held positions at several global companies, including Club Med North America, World Travel Holdings, Norwegian Cruise Line, and Oracle Corporation. In addition to her executive duties, Olivere finds time to raise funds for the Leukemia & Lymphoma Society and was chosen as Fort Lauderdale’s 2019 Woman of the Year, acknowledging her efforts.    

“The addition of Camille to our executive team brings extensive years of experience, both inside and outside of the hospitality space. We are looking forward to her driving our sales and marketing to new heights, “said Derek Fournier, President, and Chief Executive Officer, DeCurtis Corporation. “She has a proven track record of success which we are certain will support and advance our mission and vision for our clients across all sectors.”    

Olivere will officially join DeCurtis Corporation as its Senior Vice President of Sales and Marketing on July 13, 2020.

About DeCurtis Corporation

DeCurtis Corporation is the premier provider of location and proximity enabled solutions in complex indoor environments with a focus on health, safety, and security, operational enhancement, and experience evolution. Creator of Mobile Assembly Suite (MAS™), the DeCurtis Experience Platform (DXP™), and DeCurtis Shield™, DeCurtis Corporation is the leader in providing transformational experience technology based on decades of deep industry knowledge in the cruise space that is applicable to other sectors. With a vast range of experience working with some of the world’s best, most-recognized brands, DeCurtis Corporation transforms the guest experience to be safer, secure and more efficient through the creative application of the latest technology. For more information on DeCurtis Corporation, please visit http://www.decurtis.com.

Press Contact:

Stephanie Casimiro, Director of Marketing

DeCurtis Corporation

Tel: (407) 965-1395

Direct: (386) 451-1194

Email: stephanie.casimiro@decurtis.com

Web: http://www.decurtis.com

Share article on social media or email:

Cecelia Health Provides Critical Telehealth Support to Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse


Telehealth Diabetes Care

Telehealth Diabetes Care

Our experience supporting the Joslin Diabetes team and their patients during COVID-19 has highlighted the importance of the diabetes and mental health telemedicine clinic we’ll be launching this month.

In partnership with the Helmsley Charitable Trust, Cecelia Health is providing essential clinical support to people of all ages living with Type 1 and Type 2 diabetes around the country to help them overcome challenges resulting from the COVID-19 pandemic.

Since April, Cecelia Health’s team of Certified Diabetes Care and Education Specialists (CDCES) has been working with the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse and over 50 other university and hospital clinics who are receiving funding from the Helmsley Charitable Trust. They are assisting both patients and clinicians with providing a spectrum of support in managing their insulin-dependent diabetes to ease the daily burden and help improve outcomes. Cecelia Health’s telehealth model has been a critical element for providing diabetes patients with access to care at time when COVID-19 has prevented them from coming into the clinics to meet with endocrinologists and other clinical staff.

The care Cecelia Health CDCESs are providing includes:


  • Remote initiation, education, and troubleshooting continuous glucose monitors (CGM), blood glucose meters (BGM), insulin pumps and smart pen technologies combined with diabetes education to help patients more successfully manage their diabetes condition
  • Helping patients prepare for scheduled telemedicine visits by teaching them how to upload their CGM and insulin data
  • Educating them on interpreting data from their devices to highlight patterns and trends, thus streamlining and increasing the quality of their visits with the Joslin Diabetes endocrinology team

“Pre-COVID, our clinic was overcrowded, with the waiting room often completely full and providers many times working out of only one exam room.” said Dr. Ruth Weinstock, Founder and Medical Director of the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse.” Because of this, even as we re-open, telemedicine will have to continue if we are to be safe. We anticipate needing to see almost all our diabetes patients remotely until there is a vaccination.”

Accordingly, Cecelia Health CDCESs have also been working with patients on vital components of a comprehensive diabetes management plan to increase safety such as the use of glucagon, ketone meters, sick day rules, and back-up injection plans.

As the results of this partnership indicate, clinical telehealth support is an important and necessary component of an effective patient care management strategy during COVID-19 and beyond. The diabetes population is very large and growing rapidly and expensive to treat, there are not enough endocrinologists in the U.S. to support them, particularly in rural states and portions of states.

“Our experience supporting the Joslin Diabetes team and their patients during COVID-19 has highlighted the importance of the diabetes and mental health telemedicine clinic we’ll be launching this month. It will enable educating and empowering our patients to successfully manage their condition using diabetes technology, remotely monitoring them, and providing the right interventions to the right patient at the right time. This will increase access to care regardless of geography, optimize health outcomes at the lowest possible cost, and provide a great patient experience.” said Cecelia Health CEO and Founder, David Weingard.

About Cecelia Health

Cecelia Health’s mission is to transform and improve the lives of people living with chronic conditions worldwide. Cecelia Health has a proven track record of driving improved clinical outcomes and return on investment for customers. The Cecelia Health clinical team is comprised of nurses, dietitians, exercise physiologists, pharmacists, and social workers who are passionate about empowering people with chronic conditions to live rich, healthy and fulfilling lives. Cecelia Health partners with ACOs seeking to improve quality measures, and pharmaceutical and medical device companies seeking to improve adherence. Cecelia Health has also engaged in numerous joint initiatives with the JDRF, American Diabetes Association, the Diabetes Research Institute, the Association of Diabetes Care & Education Specialists, and The Helmsley Charitable Trust.

About Upstate Medical University

SUNY Upstate Medical University in Syracuse, NY, is the only academic medical center in Central New York. It is also the region’s largest employer with 9,460 employees. Affiliated with the State University of New York, Upstate’s mission is to improve the health of the community through education, biomedical research and health care. Upstate Medical University’s educational mission is anchored by its four colleges—Medicine, Nursing, Health Professions and Graduate Studies (biomedical sciences). The Upstate University Health System serves 1.8 million people, often the most seriously ill and injured, and includes Upstate University Hospital; Upstate University Hospital at Community Campus; Upstate Golisano Children’s Hospital, and numerous satellite sites.

Share article on social media or email:

Proscia Achieves Key Regulatory Milestone With Medical Device Single Audit Program (MDSAP) Certification


News Image

Proscia®, a leading provider of AI-enabled digital pathology solutions, has received Medical Device Single Audit Program (MDSAP) certification, a rigorous validation of the company’s practices for delivering high quality medical device software. This certification accelerates the company’s expansion into the diagnostic pathology market to help laboratories worldwide keep pace with the rising cancer burden and improve patient outcomes.

MDSAP was established to enable medical device manufacturers to be audited once for compliance with ISO 13485 and the standards of five different markets: United States, Australia, Brazil, Canada, and Japan. In successfully completing the MDSAP audit, Proscia has demonstrated that its quality management system satisfies strict requirements related to the design, development, production, deployment, and sale of its solutions.

“At Proscia, our commitment to quality underlies all that we do,” said Natalia Remmel, Director of Quality and Regulatory Affairs. “The MDSAP certification reflects our focus on building safe and effective solutions to help laboratories scale their digital pathology implementations as they look to deliver faster, more accurate diagnoses.”

The current standard of care for diagnosing cancer relies on the pathologist’s interpretation of patterns in tissue as viewed under a microscope. Proscia is working to transform this 150-year-old manual and subjective practice to address the growing demand for diagnostic services, as pathologists have faced a 42% increase in diagnostic workload over the last decade, and improve patient outcomes. With its Concentriq® Dx digital pathology solution and suite of AI modules, the company is accelerating workflows while driving confidence and quality gains.

Concentriq Dx enables pathologists to securely read and share cases from any location while automating time-consuming, error-prone tasks. The software can be rapidly deployed on existing IT infrastructure and works with leading scanners and laboratory information systems (LIS), offering seamless integrations with Philips, Leica, 3DHISTECH, and Hamamatsu among other solutions.

CE-marked for use in primary diagnosis in Europe, Concentriq Dx is also available for remote use in clinical practice in the United States during the COVID-19 public health emergency. This comes in response to the FDA’s recent guidance aimed at expanding the availability of digital pathology devices.

“From driving meaningful improvements in accuracy and efficiency to enabling remote case review during the public health emergency, Concentriq Dx is helping laboratories to transform their pathology operations at a time when change is more critical than ever before,” said David West, CEO of Proscia. “With our relentless dedication to quality, we are accelerating our expansion into the global diagnostic pathology market to continue advancing the standard of care.”

About Proscia

Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. For more information, visit proscia.com.

Share article on social media or email:

Mobile Solutions Releases Android as a Mobile Hotspot to Provide Control of Delivering Internet Remotely


Android as a Mobile Hotspot

Android as a Mobile Hotspot

We are living in a time of remote work and school. Organizations need solutions that enable their end users without sacrificing control and manageability. We’re excited to introduce Android as a Mobile Hotspot to meet those needs and continue growing our managed mobile offering.

Mobile Solutions is excited to announce their newest innovative solution, Android as a Mobile Hotspot. With the influx of working remotely, businesses are looking for solutions that will enable end users and allow them to maintain control. Basic mobile hotspots, used to deliver internet to remote locations or workers, lack manageability in terms of locating and remote configuration by administrators. This can leave valuable mobile endpoints vulnerable.

Hotspot devices make it easy to stay connected during the COVID-19 pandemic. This has resulted in a huge spike in demand for hotspot devices and unfortunately, this means that for many organizations, hotspots are no longer available. Mobile Solutions’ Android as a Mobile Hotspot facilitates streamlined internet access via Android devices that are locked down to kiosk hotspot mode. This solution enables organizations to provide remote working and schools to provide distance learning with ease.

Android as a Mobile Hotspot further adds to Mobile Solutions Managed Mobility Services, providing organizations with greater control of their mobile endpoints. Android devices when configured as managed mobile hotspots can provide a company administrator with:


  • Location tracking – know where your devices are located at all times.
  • Remote WiFi configuration – such as WiFi SSID/Network Name, passcode.
  • Secure control – easily block these devices from being used as hotspots, without suspending or cancelling service, allowing the device to remain manageable.

“We are living in a time of remote work and school. Organizations need solutions that enable their end users without sacrificing control and manageability. We’re excited to introduce Android as a Mobile Hotspot to meet those needs and continue growing our managed mobile offering.” – Jim Johnson, Co-Founder and CEO

About Mobile Solutions

Mobile Solutions is an award-winning SaaS company that provides a complete managed mobility practice. We make it easy for our clients to secure mobile endpoints, reduce data consumption, optimize IT spend, and simplify the management of their entire fleet of devices.

Share article on social media or email:

GuRu Releases Over-the-Air Wireless Power Developer Kit to Accelerate Innovation for Connected Devices & Solutions


News Image

GuRu received incredible feedback on prototypes unveiled earlier this year at the Consumer Electronics Show and is now excited to empower partners and OEMs for innovating products for staying powered and connected in meaningful ways.

GuRu Wireless, an innovator in developing millimeter-wave (mmWave) wireless power solutions, today announced the availability of its new evaluation and developer kit. The company’s offering facilitates testing, evaluation, and proof-of-concept designs based on GuRu’s proprietary, 24GHz, smart RF lensing technology for various scenarios, distances and devices. The kit efficiently powers devices over-the-air at distances of three feet and beyond. At 24GHz, the solution leapfrogs others to enable significantly higher power over a longer distance, while reducing overall system size and cost.

For more information on GuRu evaluation and development kits and availability, please visit https://guru.inc/guru-minievk/.

“GuRu received incredible feedback on prototypes unveiled earlier this year at the Consumer Electronics Show and is now excited to empower partners and OEMs for innovating products for staying powered and connected in meaningful ways,” said Florian Bohn, CEO of GuRu Wireless. “Via our latest evaluation kit, partners can assess potential use case scenarios and implement wireless power for desired applications.”

GuRu helps partners scale as needed according to the application, ranging from desktop to room-scale and beyond. Generator unit and recovery unit requirements, including size, power, cost, and design considerations and constraints, also factor into and drive overall system designs.

The eval kit for wireless power transmission over-the-air contains:


  • Transmitter: For desktop type environment, in a convenient, small form factor
  • Power Supply: 15/20 Volt DC for transmitter (industry-standard USB-C connector)
  • Recovery Unit: 5 Volt DC with a two-pin connector (Extra recovery units available upon request)
  • Software & Button Interface: For control and monitoring. Updates periodically available
  • Specialized Software and Hardware: Add-ons and updates available for partners


Developers can assess and incorporate GuRu’s 24GHz Smart RF Lensing power transfer, enabled via highly focused, intelligently-controlled millimeter waves for:

  • Increased power transfer, efficiency, distance
  • Smaller device size and lowered costs


About GuRu Wireless:

GuRu Wireless delivers an ecosystem of wireless power, for electronics untethered from power sources that constrict where and how they’re used. By safely projecting energy through the air via its millimeter-wave (mmWave) solution, GuRu goes beyond wires to unleash today’s portable devices, including mobile phones, IoT sensors, industrial/warehouse devices, and more. Its proprietary smart RF lensing technology enables rechargeable devices in a way that is cost-effective, scalable and applicable to enterprise or home settings.

GuRu is based in Pasadena, Calif., and funded by Kairos Ventures and Bold Capital Partners. Founded by a team of Caltech electrical engineers, applied physicists, and integrated circuit and phased array experts, the company is delivering today what was once thought impossible: a completely wire-free and limitless future.

For more information, please visit http://www.guru.inc, and join the conversation on LinkedIn and Twitter.

Media Contact:

Delia Mendoza

Venture PR

(310) 500-9273

delia@venturepr.co

Share article on social media or email:

Clean the World Endorses American Hotel & Lodging Association’s Safe Stay Initiative


Clean the World Endorses American Hotel & Lodging Association’s Safe Stay Initiative

“The Safe Stay initiative is a comprehensive collection of resources, best practices, and protocols developed by leaders from various aspects of the hotel industry. This is a big win for hotels and takes the guesswork out of how to properly re-open and what expectations to provide to guests.”

Clean the World, a global leader in water, sanitation, hygiene, and sustainability, is endorsing the American Hotel & Lodging Association’s new Safe Stay initiative. The Safe Stay initiative will seek to change hotel industry norms, behaviors, and standards to ensure both hotel guests and employees are confident in the cleanliness and safety of hotels as travel resumes. It includes checklists for enhanced cleaning practices workplace protocols and employee training to meet the new health and safety challenges and more.

“The Safe Stay initiative is a comprehensive collection of resources, best practices, and protocols developed by leaders from various aspects of the hotel industry. This is a big win for hotels and takes the guesswork out of how to properly re-open and what expectations to provide to guests,” says Shawn Seipler, Founder, and CEO, Clean the World.

AHLA’s initiative is focused on enhanced hotel cleaning practices, social interactions, and workplace protocols to meet the new health and safety challenges and expectations presented by COVID-19. The guidelines were created by an Advisory Council comprised of leaders from all segments of the hotel industry in accordance with CDC best practices. Safe Stay is endorsed by all major U.S. hotel brands, associations in all 50 states, and Canada and is quickly becoming the industry’s go-to guidelines as hotels look to re-open.

“Every hotel guest and employee should know that their health and safety are our top priority,” said Chip Rogers, president, and CEO of AHLA. “Safe Stay represents a new level of focus for an industry already built on cleanliness. Hotels have always had rigorous standards for cleaning and safety. With Safe Stay, we are enhancing these standards to help create peace of mind. As travel resumes, hotels are ready to safely welcome back the traveling public.”

For more information, please visit: https://www.ahla.com/safestay

About Clean the World

Clean the World is a social enterprise dedicated to WASH (water, sanitization, and hygiene) and sustainability. It operates soap recycling centers and offices in Orlando, Montreal, Las Vegas, Hong Kong, Netherlands, Washington DC, and Punta Cana and leads a “Global Hygiene Revolution” to distribute recycled soap and hygiene products from more than 8,000 hotel, resort, and cruise partners. Clean the World’s foundation provides WASH (water, sanitization, and hygiene) programming to benefit global communities with high pre-adolescent death rates due to acute respiratory infection (pneumonia) and diarrheal diseases (cholera) – which are two of the top killers of children under the age of five. Since 2009, the foundation has served over 10 million individuals and distributed 56 million bars of soap and 5 million hygiene kits in 127 countries. For more information on how you can participate in Clean the World’s world-renowned recycling program, please visit https://cleantheworld.org/get-involved/hotel-recycling-program/

About AHLA

The American Hotel & Lodging Association (AHLA) is the sole national association representing all segments of the U.S. lodging industry and contributes nearly $660 billion to U.S. GDP. Headquartered in Washington, D.C., AHLA focuses on strategic advocacy, communications support, and workforce development programs to move the industry forward. Every day, America’s hotels make dreams come true, not just for our guests, but also for the 8.3 million people whose jobs we support—more than 1 in every 25 American jobs. Learn more at http://www.ahla.com.

MEDIA CONTACTS:

Sandie Beauchamp

Clean the World

info@cleantheworld.org

407-574-8353

Maura Morton

AHLA

mmorton@ahla.com

202-381-8644

Share article on social media or email:

Palette Life Sciences Continues Global Expansion of Deflux Availability with New Saudi Arabian Distribution Partner, Gulf Horizon Co. Ltd. (GHIM)


News Image

This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients in the region” James Leech, Palette Life Sciences

Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced its latest distribution agreement with Gulf Horizon Co. Ltd. (GHIM). GHIM will distribute Palette’s product, Deflux, in Saudi Arabia. GHIM is a medical equipment company that provides hospitals with innovative medical devices for minimally invasive surgery in the Kingdom of Saudi Arabia (KSA). This new distribution agreement with GHIM further extends Palette’s global expansion efforts, and marks the first time Deflux has been directly registered within the KSA.

“This distribution partnership and registration within Saudi Arabia allows Palette to establish a beachhead within the Middle East, and is an excellent starting point to ensure long-term access to our innovative products for customers and patients within the region,” said James Leech, Head of Corporate Development, Palette Life Sciences. “GHIM has vast experience and deep physician relationships within the KSA. We are confident that GHIM will be an excellent partner to aid in our delivery of high quality solutions to physicians and patients. Palette Life Sciences is dedicated to supporting physicians globally in their pursuit of improved patient outcomes. Palette and its network of partners are making several significant investments within local markets to improve physician access to Palette resources, including renewed product training and support.“

For more information or to place an order within a GHIM territory, please contact a GHIM representative at jamil@ghim-sa.com.

About Deflux

Deflux is a minimally invasive, outpatient treatment that has been proven safe and effective in children with vesicoureteral reflux (VUR). VUR is a serious paediatric urinary condition in which urine refluxes from the bladder through one or both ureters toward the kidneys, due to an abnormality at the junction of the ureter and the bladder. Deflux is an injectable gel bulking agent made from two tissue-friendly polysaccharides; Non-Animal Stabilised Hyaluronic Acid (NASHA®) and dextranomer (Dx) microspheres. The product is administered via injection around the ureteral opening to prevent urine reflux. Deflux is indicated for children with all VUR grades and is the recommended first-line treatment for VUR.1 Separate study results show Deflux is an efficacious long-term (15 – 25 years) treatment option for VUR grade IV2 with up to 93% success rates after a one time injection and no post-injection febrile UTIs (19 month results).3 Deflux is the only minimally invasive VUR treatment approved globally across Australia, Canada, Europe, Latin American, Japan, New Zealand and the United States.

About Palette Life Sciences AB

Palette Life Sciences is a fully integrated life sciences company. Palette’s products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux®, Solesta® and Barrigel®. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, and Dallas, Texas. Learn more at http://www.palettelifesciences.com.

References:

1. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infection in patients with vesicoureteral reflux. Curr Med Res Opin. 2007;23(4):S15-20.

2. Stenbäck A, Olafsdottir T, Sköldenberg E, Barker G, Läckgren G. Non-animal hyaluronic acid/dextranomer gel (Deflux®) endoscopic treatment in grade IV VUR results after 15-25 years: durable and effective. J Pediatr Urol. 2020.

3. Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. J Pediatr Urol. 2012;9(4)359-365.

Q-Med AB is the current legal manufacturer and holds the CE Mark.

Deflux®, GHIM®, NASHA®, and Palette Life Sciences™ are registered trademarks.

All rights reserved. APM209A

Share article on social media or email:

modern clinical technology helps scientists to accelerate the development of new therapies and vaccines


The durability, near real time performance and quality of data collection, processing and analysis are instrumental in our daily operations and it is enormously important in the COVID-19 studies

EDETEK, the premier provider of digital clinical trial computer systems, today announced that the company’s cloud-based eClinical and clinical informatics platforms CONFORM™ are supporting multiple clinicals sponsors in research and development of emergent COVID-19 treatments and vaccines.

Jian Chen, EDETEK’s President and CEO, “Our customers use CONFORM ™ in Phase I, II and III COVID-19 clinical trials. In some trials our Platform is used entirely as an end to end clinical system. Customers also implemented selective CONFORM™ components to add efficiency to the existing development workflows. It is exciting to see how rapidly our team and the system can fit into the emergent research and development of the COVID-19 therapies and vaccines. We have invested years in development of the state of the art comprehensive and highly configurable clinical system and I am thrilled to see how it is helping scientists battle the global pandemic”.

The CONFORM™ eClinical suite of study conduct applications is utilized for patient randomization, clinical supply, trial and document management, drug safety monitoring and electronic data capture. CONFORM™ Informatics platform enables rapid ingestion of clinical structured and unstructured data from a variety of clinical data providers, data aggregation, validation, transformation, review and reporting in one system that quickly integrates with information consumers – processes and systems of study sponsors and sites. In the case of COVID-19, CONFORM™ studies were configured, tested, and deployed in a matter of days to meet the highly challenging timelines of clinical development teams.

CONFORM™ was architected to support modern clinical trials that concurrently use variety of systems to collect information. EDC, laboratory systems, instruments, IoT patient wearable devices, imaging, ePRO smart phones, EHR applications represent a typical set of digital sources in a trial. COVID-19 trials employ many of these data providers to study different safety and efficacy indicators in record time.

“Using the capabilities of our Information Hub and Clinical Data Lake to quickly connect and aggregate the data were keys in these implementations. Another main differentiator of CONFORM™ is the event driven model. CONFORM™ is fully event driven and it processes any business and scientific events as well as data loads in real time according to sponsors’ workflow and study configuration. The durability, near real time performance and quality of data collection, processing and analysis are instrumental in our daily operations and it is enormously important in the COVID-19 studies where we receive tens of thousands of data transmissions every day and run complete study data processing and reporting tasks several times a day. The era of a slow-going typical EDC study with a nightly processing batch is gone. COVID-19 has shown us that the traditional model is no longer working”, states Peter Smilansky, Senior Vice President of Product Development and Strategy of EDETEK.

CONFORM™ GxP–compliant technology platform is natively designed for scalable cloud computing. It runs on Amazon Web Services supporting COVID-19 and hundreds of other clinical trials on three continents.

ABOUT EDETEK

EDETEK, Inc. is an innovative clinical solutions company that provides high-quality technology and services to pharmaceutical, biotechnology, and medical device companies. We utilize our clinical platform, CONFORM™, to fulfill our clients’ data engineering, computational and scientific analytics needs. Visit our website at http://www.edetek.com.

Share article on social media or email:

Eos Energy Storage Further Strengthens Leadership with New Chief Financial Officer & Chief Strategic Alliances Officer


photos of Kurada and Treece with the Eos logo

Sagar C. Kurada joins Eos as Chief Financial Officer and former CFO Mack Treece has moved to a broader management role as Chief Strategic Alliances Officer.

Eos is entering a period of tremendous growth, and it is paramount that we have a solid leadership team that understands the opportunities for expansion.

Eos Energy Storage, the leading manufacturer of safe, low-cost, and long-duration zinc battery storage systems, is proud to announce the appointment of a Sagar C. Kurada to Chief Financial Officer. Sagar will join the management team to help drive the future growth of Eos. The timing of this announcement comes on the heels of news that B. Riley Principal Merger Corp. II has entered a business combination transaction which will result in Eos becoming a publicly listed company.

“Eos is entering a period of tremendous growth, and it is paramount that we have a solid leadership team that understands the opportunities for expansion,” commented Joe Mastrangelo, CEO of Eos. “Sagar complements our team and brings the exceptional finance experience and skills that are needed as we transition into a publicly-traded company. Mack has made tremendous contributions to help bring Eos to its current level. Building a strong ecosystem is an important aspect of our business growth and I look forward to Mack’s contributions. I am excited to welcome Sagar to our team and I congratulate Mack on his new role.”

As CFO, Sagar will be responsible for Eos’ overall financial strategy and direction, overseeing all financial functions to guide the controller, treasury, shareholder relations, accounting, tax, financial planning, and internal audit functions. He will lead the financial operations as the company executes on its growth strategy and exceeds its clients’ and investors’ expectations.

“I’m proud to be a part of the future of sustainable energy and have found an excellent fit with the team of Eos,” commented Sagar. “As we move forward, I am committed to maximizing long-term shareholder value, ensuring a balanced portfolio of growth initiatives, and maintaining the high level of integrity and transparency for which Eos is known.”

Prior to joining Eos, Sagar held previous CFO roles with HighTower Advisors and in multiple GE operating entities, and he also worked in the private equity consulting practice at FCM. Throughout his 20-year career in financial strategy, planning, accounting, auditing, Sagar has established a reputation for building world-class teams and for aligning financial and business interests to support business strategy and high-growth. He has led multiple equity and debt financing rounds and raised significant capital to support business growth. Sagar holds a BS in Finance and Technology from Rensselaer Polytechnic Institute and an MBA from Columbia Business School.

With Eos’ recent letter of intent with B. Riley Principal Merger Corp. II, Eos will become a publicly listed company and see approximately $225 million of additional new equity financing. As CFO of Eos, Sagar will leverage his knowledge and more than 20 years of experience to support delivering enterprise value and business growth.

About Eos Energy Storage

At Eos, we are on a mission to accelerate clean energy by deploying stationary storage solutions that can help deliver the reliable and cost-competitive power that the market expects in a safe and environmentally sustainable way. Armed with a patent for a membrane-free zinc battery technology, Eos has been pursuing this opportunity since 2008 when it was founded. Eos Energy Storage has 10+ years of experience in battery storage testing, development, deployment, and operation. The Eos Aurora® system integrates the Company’s aqueous, zinc battery technology (Znyth®) to provide a safe, scalable, and sustainable alternative to Lithium Ion. https://eosenergystorage.com/.

Share article on social media or email:

Schlesinger Groups Brands Its Clinical Division as Schlesinger Clinical Research


News Image

Rob Ramirez, EVP Strategic Development

This offering streamlines the research process by bringing site selection, subject enrollment, and study execution expertise under one partner

Schlesinger Clinical Research addresses an unmet need in the market by encompassing all data collection aspects necessary for clinical research under one roof. The company boasts thirty proprietary sites and expert team with principal investigation experience, as well as CITI-certification in Good Clinical Practice and Human Subjects Protection to ensure adherence to study protocols.

Schlesinger Clinical Research offers a single point of contact to oversee the recruitment and consistent application of clinical study research protocols nationwide. The company specializes in Rx-to-OTC and Non-Rx product research that often involves IRB approval and FDA submissions. Schlesinger Clinical Research has worked with many of the world’s largest universities, CROs, CPG, pharma, and insight companies.

As an approved government vendor and fully FDA CFR Part-11 compliant, the company is currently supporting electronic nicotine delivery system (ENDS) manufacturers who are seeking a partner to streamline their clinical testing to meet the September 9th submission deadline for the FDA Premarket Tobacco-Product Applications (PMTA).

The addition of Schlesinger Clinical Research adds high quality regulated research to Schlesinger Group’s portfolio of capabilities, and underscore its position as a highly comprehensive data collection and research services provider.

Commenting on the news, Rob Ramirez, EVP, Strategic Development at Schlesinger Group, said, “This offering streamlines the research process by bringing site selection, subject enrollment, and study execution expertise under one partner for better outcomes”

Share article on social media or email: